Loading clinical trials...

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

NCT05567783•Vir Biotechnology, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIR-2482 compared to placebo in preventing influenza A illness in healthy adults 18 to \<65 years of age without pre-existing risk factors for serious complications from influenza infection.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Participant must be 18 to \< 65 years of age, at time of randomization
•Participants must be in good health, determined from medical history and no clinically significant findings from physical examination, 12-lead electrocardiogram (ECG), vital signs, and laboratory values

Exclusion Criteria

•History or clinical evidence of conditions considered high risk for developing influenza-related complications
•History of confirmed influenza infection within 3 months prior to randomization.
•Febrile illness with or without respiratory symptoms
•History of malignancy within 5 years or participant is under evaluation for malignancy.
•Any condition or receipt of any medication contraindicating IM injection, as judged by the investigator.
•History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis
•Participant has a clinically significant medical condition, physical exam finding, or abnormal laboratory result.
•Prior or planned receipt of any influenza vaccine for the upcoming season.
•Received any investigational agent within 90 days or within 5 half-lives of the investigational agent.

Locations (51)

Investigative Site

Anniston, Alabama, United States

Investigative Site

Mobile, Alabama, United States

Investigative Site

Tempe, Arizona, United States

Investigative Site

Long Beach, California, United States

Investigative Site

Pomona, California, United States

Investigative Site

San Diego, California, United States

Investigative Site

Aurora, Colorado, United States

Investigative Site

Longmont, Colorado, United States

Investigative Site

Fort Myers, Florida, United States

Investigative Site

Jupiter, Florida, United States

Key Dates

Start Date

October 30, 2022

Primary Completion Date

May 5, 2023

Completion Date

August 31, 2023

Last Updated

September 19, 2024

Enrollment

2,977

ACTUAL participants

Conditions

Influenza A

Interventions

VIR-2482 (450 mg)

BIOLOGICAL

VIR-2482 (1200 mg)

BIOLOGICAL

Placebo

BIOLOGICAL

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

NCT07128615

Influenza A

View study

ACTIVE_NOT_RECRUITINGPHASE1

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

NCT04896853

COVID-19 Acute Respiratory Distress SyndromeInfluenza A+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Inclusion Criteria

Exclusion Criteria

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

CC-42344 Safety Study in Healthy Participants

Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings